Get BioSpectrum Asia along with 5,000 + other magazines &amp; newspapers

“We are planning to launch a new bioprocess controller in Q1 2021”

Bioprocess engineers develop and produce a multitude of products and ingredients available today. Their applications are diverse, and the products can be found in pharmaceutical, chemical, and nutrition industries. With an integrated portfolio comprising software, instruments, consumables, and services, Eppendorf can satisfy the demands of bioprocess development through production. To find out about what major is in store at Eppendorf Bioprocess, BioSpectrum spoke to Richard Mirro, Business Manager, Bioprocess at Eppendorf, Inc., US.

4 mins read

“We are confident that Sputnik V will be providing long-term immunization defence against potential new coronavirus infections”

On December 14, 2020, Moscow’s National Research Center for Epidemiology and Microbiology named ‘Gamaleya Center’ and the Russian Direct Investment Fund (RDIF) announced the efficacy of over 90 per cent of the Russian Sputnik V vaccine in Phase III post-registration clinical trials. RDIF joins partners and manufacturers in ramping up the production of Sputnik V. First batch of 300,000 doses of Sputnik V vaccine has already been delivered to Argentina by RDIF on December 24, 2020. In an interview with BioSpectrum Asia Kirill Dmitriev, CEO, Russian Direct Investment Fund (RDIF), Russia shared more insight on the encouraging efficacy data of the Sputnik V with Biospectrum Asia.

4 mins read

“Australia has reinforced its standing as a world-class destination for early phase clinical development”

Avance Clinical, a leading Australian Contract Research Organization (CRO) for biotech firms, and winner of the prestigious Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award, has recently partnered with Europe’s leading CRO, Cromos Pharma. The collaboration will allow biotech firms to quickly start their pre-IND early phase studies in Australia, thereafter, expanding to Central/Eastern Europe to access the large patient populations for their Phase II and III studies. In an email interaction with BioSpectrum, Yvonne Lungershausen, CEO, Avance Clinical, Australia spoke about the Australian CRO market, and the impact of COVID-19 crisis.

4 mins read

Evaluating COVID-19 vaccines on mutant viral strains

While the viral variants and vaccine trials are contesting with each other, Norway based Coalition for Epidemic Preparedness Innovations (CEPI) has launched a first-of-its-kind collaboration to tackle emergence of new COVID-19 viral strains and evaluate their impact on vaccine candidates in development. Tracking viral mutations and diversity is essential to ensure efficacy of COVID-19 vaccine candidates on mutant virulent strains.

5 mins read

Taiwan initiates new measures for management of medical masks

Taiwan has initiated two new measures to reinforce the management of medical masks.

HiMedia gets multiple nods for COVID-19 products

HiGenoMB, the molecular biology division of Indian firm HiMedia Laboratories has received the CE/IVD approval and a nod from the Indian Council of Medical Research (ICMR) for its COVID-19 range of products.

EuBiologics partners with IVI for COVID-19 vaccine development

The International Vaccine Institute (IVI) and South Korean company EuBiologics have exchanged a Memorandum of Understanding (MoU) to cooperate in the clinical development of the COVID-19 vaccine the company is currently developing.

2021 beckons MAJOR investments IN R&D

The life sciences industry in Asia Pacific (APAC) region entered the year 2020 with companies entering into new agreements for expansion and focusing on applied research to develop new drugs that are affordable. During 2020, the industry, which acted timely, as covered in the January 2020 issue of BioSpectrum Asia, witnessed unprecedented collaborations with the governments due to the unexpected spread of coronavirus since December 2019. COVID-19 is expected to remain a defining issue for the life sciences industry across the globe in 2021, compelling companies to invest heavily in research and development.

6 mins read

Singapore Gives Nod To Pfizer-BioNtech Covid-19 Vaccine

The Health Sciences Authority (HSA) has granted an authorization under the Pandemic Special Access Route (PSAR) for the Pfizer-BioNTech COVID-19 vaccine to be used in Singapore for the prevention of COVID-19.